CCAP Crescent Capital BDC, Inc. Insider Trading

President Henry Chung buys 4,500 shares of CCAP at $11.45; 3 other insiders also bought within 14 days. Stock down -28.7% from 52-week high.

Henry Chung, President of Crescent Capital BDC, Inc., purchased 4,500 shares at $11.45, bringing his holdings from 16,222 shares to 20,722 shares (a +27.7% increase in his position). The transaction occurs amid a cluster of buying activity: 3 other insiders also purchased shares within the past 14 days. The current price of $11.44 is -28.7% from the 52-week high of $16.04, representing significant recent decline. The company reported net income of $-15,513,000.00, adding complexity to the valuation context. This filing signals sustained insider accumulation across multiple executives during a period of depressed share prices relative to recent highs.

CCAP CEO Jason Breaux buys 5,000 shares at $11.19; cluster of 2 other insider buys in past 14 days as stock down 28.7% YTD.

Jason Breaux, CEO of Crescent Capital BDC, purchased 5,000 shares at $11.19 on 2026-05-20, increasing his holdings from 47,636 shares to 52,636 shares. This purchase occurs within a cluster pattern—2 other insiders also bought within the past 14 days—while the stock has declined 28.7% from its 52-week high of $16.04 and dropped 15.3% over the past 30 days. The CEO's purchase at depressed price levels, coordinated with concurrent insider buying activity, occurs despite the company reporting negative net income of $-15,513,000.00, a metric that contexualizes the stock's recent weakness. The cluster buy pattern and CEO participation at a significantly lower valuation point warrant attention to whether this reflects insider assessment of value or a response to operational headwinds.

CFO Lombard Gerhard buys 1,000 shares of CCAP at $11.12; stock down 30.7% from 52-week high, trading -16.4% in 30 days.

Lombard Gerhard, Chief Financial Officer of Crescent Capital BDC, purchased 1,000 shares at $11.12 on 2026-05-18, increasing his holdings from 36,373 to 37,373 shares. The transaction occurred amid notable weakness in CCAP: the stock is trading at $11.37, down 30.7% from its 52-week high of $16.40 and down 16.4% over the past 30 days. Gerhard's prior buy at this ticker on 2025-11-17 posted positive 30d and 90d returns, marking 1 of 1 prior buys well-timed at the 90-day mark. However, the current purchase takes place as the company reports a net loss of $-15,513,000.00 and carries a P/E of 27.73, suggesting the recent price decline has not yet fully reflected fundamental weakness. The modest size of this transaction relative to his existing holdings (2.7% increase) and the deteriorating short-term price momentum warrant closer examination of the underlying motivation.

Director Strandberg buys 85,000 CCAP shares at $11.28; holdings rise to 201.1K shares (+73.2%)

Steven F. Strandberg, a director at Crescent Capital BDC, purchased 85,000 shares at $11.28 on 2026-05-19, increasing his holdings from 116.1K to 201.1K shares (a 73.2% increase in position size). The transaction totaled $958.5K. The timing occurs against a backdrop of significant stock weakness: the current price of $11.37 is -30.7% from the 52-week high of $16.40 and down -16.4% over the prior 30 days. The company is reporting net losses ($-15.5M) rather than profits, which adds context to the valuation at which this purchase occurred. This discrete purchase by a director warrants monitoring as a data point in the broader market and fundamental environment for the company.

CCAP CFO Gerhard buys 2,000 shares at $13.34; stock down 12.1% in 90 days from peak

Lombard Gerhard, the CFO of Crescent Capital BDC, purchased 2,000 shares at $13.34 on 2025-11-17, bringing his total holdings to 34,284 shares. The stock is currently trading at $13.33, off 33.4% from its 52-week high of $20.00 and down 12.1% over the past 90 days. The company shows a P/E of 13.74 with net income of $7,102,000.00, suggesting a stable earnings backdrop. An insider acquisition by the CFO during a sustained downtrend warrants observation of subsequent price action and any forward guidance disclosures to assess whether this represents a deliberate accumulation decision or routine portfolio activity.

Controller Kirill Bouek buys 200 CCAP shares at $15.67; holdings rise to 1,057 shares (+23.3%)

Kirill Bouek, Controller at Crescent Capital BDC, Inc., purchased 200 shares at $15.67 on 2025-08-28, increasing his holdings by 23.3% to 1,057 shares. The purchase occurred within the stock's 52-week range of $14.10–$20.00, at a price 21.4% below the 52-week high. The company trades at a P/E of 13.20 with a market cap of $582.2M and reported net income of $15.0M. The transaction represents a routine portfolio action by a mid-level officer; without additional context on planned disposition or prior trading patterns at this ticker, the acquisition warrants standard monitoring but does not indicate material strategic signaling at the enterprise level.

CCAP Managing Director Barrios Raymond buys 3,245 shares for $50,712.77 in 2 transactions on 2025-08-25

Barrios Raymond, Managing Director of Crescent Capital BDC, Inc. (CCAP), executed 2 separate purchases on 2025-08-25 totaling 3,245 shares for $50,712.77 at a blended average price of $15.63, increasing his holdings by 20.4% from 15,932 to 19,177 shares. The transaction occurred at a price 21.8% below the 52-week high of $20.00, near the lower end of the 52-week range ($14.10–$20.00), and represents a meaningful accumulation by an insider in a material leadership position. The company's P/E of 13.13 and trailing net income of $15,013,000.00 provide a valuation context, though the significance of this purchase by a Managing Director—particularly the two-transaction structure on a single day—merits investor attention to understand the underlying rationale.